What the Study Reported
Three years after lecanemab became the first anti-amyloid antibody granted traditional FDA approval, its manufacturers have released data on how it has performed outside a clinical trial.
Three years after lecanemab became the first anti-amyloid antibody granted traditional FDA approval, its manufacturers have released data on how it has performed outside a clinical trial.